Immune Checkpoint Inhibitors: all 7,814 studies that test it

Page 72 of 79. Open to participants first (2,629), then studies with results posted, then the rest; newest registration first within each.

• Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]Status unknownNCT03439501Phase 2
• Combination of Chemoradiation With Immunotherapy in Inoperable œsophageal CancerTerminatedNCT03437200Phase 2
• Pembrolizumab With Intratumoral Injection of Clostridium Novyi-NTActive, not recruitingNCT03435952Phase 1
• Epacadostat and Pembrolizumab in Treating Participants With Advanced Pancreatic CancerWithdrawnNCT03432676Phase 2
• Anti-PD-1 in Combination With Chemotherapy as First-Line Treatment to Lung CancerCompletedNCT03432598Phase 2
• Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian CancerCompletedNCT03430518Phase 1
• A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic MelanomaCompletedNCT03430297Phase 3
• PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal CarcinomaActive, not recruitingNCT03427827Phase 3
• Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV MelanomaTerminatedNCT03425461Phase 1
• A Longitudinal Assessment of Tumor Evolution in Patients With Brain CancerCompletedNCT03425292Phase 1
• Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose TherapyTerminatedNCT03422523Phase 2
• Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated GlioblastomaTerminatedNCT03422094Phase 1
• AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung CancerCompletedNCT03421353Phase 1
• Study of Atezolizumab + FLOT vs. FLOT Alone in Patients With GC/GEJ and High Immune ResponsivenessActive, not recruitingNCT03421288Phase 2
• Pembrolizumab in Hepatocellular CarcinomaActive, not recruitingNCT03419481Phase 2
• GRN-1201 With Pembrolizumab in Subjects With Metastatic PD-L1+ NSCLCTerminatedNCT03417882Phase 2
• A Multicenter Open-label Phase II Trial to Evaluate Nivolumab and Ipilimumab for 2nd Line Therapy in Elderly Patients With Advanced Esophageal Squamous Cell CancerCompletedNCT03416244Phase 2
• Pembrolizumab With Chemotherapy in Front Line Advanced Ovarian, Primary Peritoneal and Fallopian Tube CancerStatus unknownNCT03410784Phase 2
• Cisplatin + Radiotherapy vs Durvalumab + Radiotherapy Followed by Durvalumab vs Durvalumab + Radiotherapy Followed by Tremelimumab + Durvalumab in Intermediate-Risk HPV-Positive Oropharyngeal SCCActive, not recruitingNCT03410615Phase 2
• Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in HER2 Positive EsophagoGastric AdenocarcinomaCompletedNCT03409848Phase 2
• Phase IIb Study Evaluating Immunogenic Chemotherapy Combined with Ipilimumab and Nivolumab in Breast CancerCompletedNCT03409198Phase 2
• Apatinib With Pembrolizumab in Previously Treated Advanced MalignanciesTerminatedNCT03407976Phase 1
• A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)CompletedNCT03407105Phase 1
• MGD009/MGA012 Combination in Relapsed/Refractory CancerCompletedNCT03406949Phase 1
• Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer.CompletedNCT03406650Phase 2
• A Multicentre Phase II Trial of Durvalumab Versus Physician's Choice Chemotherapy in Recurrent Ovarian Clear Cell AdenocarcinomasStatus unknownNCT03405454Phase 2
• Avelumab in Refractory Testicular Germ Cell Cancer.CompletedNCT03403777Phase 2
• ALCMI-005: Pembrolizumab and Epacadostat in Treating Patients With Extensive Stage Small Cell Lung CancerWithdrawnNCT03402880Phase 2
• A Study to Evaluate Apatinib (Also Known as Rivoceranib) Plus Nivolumab in Participants With Unresectable or Metastatic CancerCompletedNCT03396211Phase 1
• Avelumab With Decitabine as First Line for AML Treatment of Patients With AML, Who Are Unfit for Intensive ChemotherapyTerminatedNCT03395873Phase 1
• Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal AdenocarcinomaCompletedNCT03395847Early Phase 1
• A Trial of SHR-1210 (an Anti-PD-1 Antibody) in Combination With Apatinib in Patients With Advanced TNBCCompletedNCT03394287Phase 2
• Study of AZD9150 and MEDI4736 (Durvalumab) in Japanese Adult Patients With Advanced Solid MalignanciesCompletedNCT03394144Phase 1
• Combination of Immunotherapy and Hyperthermia in Advanced Malignant MesotheliomaTerminatedNCT03393858Phase 1/2
• Study of Pembrolizumab Plus Fulvestrant in Hormone Receptor Positive, HER-2 Negative Advanced/Metastatic Breast Cancer PatientsActive, not recruitingNCT03393845Phase 2
• A Phase I Clinical Study for Evaluating the Safety of MASCT-I in Advanced Soild TumorStatus unknownNCT03393416Phase 1
• Nivolumab and Ipilimumab With or Without Local Consolidation Therapy in Treating Patients With Stage IV Non-Small Cell Lung CancerActive, not recruitingNCT03391869Phase 3
• A Study of Avelumab in Penile Cancer Who Are Unfit for or Have Progressed After Platinum-Based ChemotherapyActive, not recruitingNCT03391479Phase 2
• Nivolumab as Treatment for Recurrent/Metastatic Nasopharyngeal Carcinoma After Failing 2 Lines or More Previous ChemotherapyWithdrawnNCT03390738Phase 2
• Avelumab Plus Carboplatin-gemcitabine in Urothelial CarcinomaCompletedNCT03390595Phase 2
• Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib TreatmentCompletedNCT03389126Phase 2
• Neo-Adjuvant Bladder Urothelial Carcinoma COmbination-immunotherapyCompletedNCT03387761Phase 1
• A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)Active, not recruitingNCT03385226Phase 2
• Propranolol Hydrochloride and Pembrolizumab in Treating Patients With Stage IIIC-IV Melanoma That Cannot Be Removed by SurgerySuspendedNCT03384836Phase 1/2
• A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or AblationActive, not recruitingNCT03383458Phase 3
• Chemoradiation vs Immunotherapy and Radiation for Head and Neck CancerActive, not recruitingNCT03383094Phase 2
• Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular CarcinomaTerminatedNCT03382886Phase 1
• IRX-2 Regimen and Durvalumab, for Incurable H&N Squamous Cell CarcinomaCompletedNCT03381183Phase 1
• Haploidentical Lymphocytes With Nivolumab/Ara-C as Consolidation in Elderly AML PatientsTerminatedNCT03381118Phase 2
• A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung CancerCompletedNCT03380871Phase 1
• A Study of the Safety and Antitumoral Efficacy of Nivolumab After SIRT for the Treatment of Patients With HCCCompletedNCT03380130Phase 2
• Pembrolizumab (MK-3475) as Maintainance in Treated Patients With Unresectable Stage III NSCLCStatus unknownNCT03379441Phase 2
• Definitive CCRT Combined With Durvalumab and Tremelimumab for Inoperable Esophageal CancerStatus unknownNCT03377400Phase 2
• Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic CancerStatus unknownNCT03374293Phase 2
• Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/LymphomaStatus unknownNCT03374007Phase 1
• VX15/2503 and Immunotherapy in Resectable Pancreatic and Colorectal CancerCompletedNCT03373188Phase 1
• Pilot Study of Nilogen 3D-EX and Its Ability to Predict Therapeutic Response to Anti-PD1 or Anti-PDL1 in NSCLCStatus unknownNCT03371992Early Phase 1
• Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung CancerCompletedNCT03371979Phase 1/2
• A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin LymphomaWithdrawnNCT03369964Phase 1
• Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma PatientsCompletedNCT03366272Phase 2/3
• BEACON - ABC in Recurrent Platinum Resistant HGSOCActive, not recruitingNCT03363867Phase 2
• SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell LymphomaStatus unknownNCT03363555Phase 2
• Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland TumorsActive, not recruitingNCT03360890Phase 2
• Apatinib Plus Anti-PD1 Therapy for Advanced OsteosarcomaCompletedNCT03359018Phase 2
• Avelumab With Valproic Acid in Virus-associated CancerCompletedNCT03357757Phase 2
• PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)TerminatedNCT03357224Phase 2
• Safety and Efficacy of Durvalumab Combined to Neoadjuvant Chemotherapy in Localized Luminal B HER2(-) and Triple Negative Breast Cancer.CompletedNCT03356860Phase 1/2
• BrUOG 354 Nivolumab +/- Ipilimumab for Ovarian and Extra-renal Clear Cell CarcinomasActive, not recruitingNCT03355976Phase 2
• Atezolizumab With Bevacizumab and Chemotherapy vs Bevacizumab and Chemotherapy in Early Relapse Ovarian CancerCompletedNCT03353831Phase 3
• Avelumab Treatment in Patients With Neuroendocrine Carcinomas (NEC G3) Progressive After ChemotherapyCompletedNCT03352934Phase 2
• Study of the Safety, Pharmacokinetics, and Antitumor Activity of AK105 in Subjects With Advanced Solid TumorsCompletedNCT03352531Phase 1
• Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC PatientsCompletedNCT03351361Phase 3
• iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and IpilimumabActive, not recruitingNCT03350126Phase 2
• Regorafenib Plus Pembrolizumab in First Line Systemic Treatment of HCCCompletedNCT03347292Phase 1
• Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLsStatus unknownNCT03346642Phase 1/2
• Durvalumab (MEDI4736) in Frail and Elder Patients With Metastatic NSCLC (DURATION)CompletedNCT03345810Phase 2
• Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins LymphomaCompletedNCT03343665Phase 1/2
• A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's LymphomaCompletedNCT03343652Phase 1/2
• Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer PatientsTerminatedNCT03342417Phase 2
• Nivolumab Plus Epacadostat in Combination With Chemotherapy Versus the EXTREME Regimen in Squamous Cell Carcinoma of the Head and Neck (CheckMate 9NA/ECHO-310)WithdrawnNCT03342352Phase 3
• Neoadjuvant AXITINIB and AVELUMAB for Patients With Localized Clear-cell RCCStatus unknownNCT03341845Phase 2
• Avelumab With Laser Interstitial Therapy for Recurrent GlioblastomaCompletedNCT03341806Phase 1
• Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal CancerWithdrawnNCT03340558Phase 2
• Doxorubicin Alone Versus Atezolizumab Alone Versus Doxorubicin and Atezolizumab in Recurrent Cervical CancerActive, not recruitingNCT03340376Phase 2
• ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin LymphomaActive, not recruitingNCT03337919Phase 2
• Pembrolizumab as Neoadjuvant Treatment in HCCStatus unknownNCT03337841Phase 2
• An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker AssessmentCompletedNCT03335540Phase 1
• Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsActive, not recruitingNCT03333616Phase 2
• A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin LymphomaActive, not recruitingNCT03331731Phase 2
• Combination Study of SV-BR-1-GM With RetifanlimabCompletedNCT03328026Phase 1/2
• Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors That Cannot Be Removed by SurgeryWithdrawnNCT03326258Phase 1/2
• Neoadjuvant Pembrolizumab + Epacadostat Prior to Curative Surgical Care for Squamous Cell Carcinoma of the Head and NeckWithdrawnNCT03325465Phase 2
• First-line Gemcitabine/Cisplatin +/- Avelumab in Locally Advanced or Metastatic Bladder CarcinomaTerminatedNCT03324282Phase 2
• Testing the Addition of an Immunotherapy Agent, Atezolizumab, When Given With the Usual Chemo-Immunotherapy Drug Combination (Rituximab Plus Gemcitabine and Oxaliplatin) for Relapsed/Refractory (That Has Come Back or Not Responded to Treatment) Transformed Diffuse Large B-Cell LymphomaActive, not recruitingNCT03321643Phase 1
• Combination of Durvalumab and Tremelimumab as Maintenance Treatment in Patients With Non Squamous and Squamous (NSCLC)WithdrawnNCT03319316Phase 2
• REirradiation and Programmed Cell Death Protein 1 (PD-1) Blockade On Recurrent Squamous Cell Head and Neck TumorsCompletedNCT03317327Phase 1/2
• Modern Immunotherapy in BCG-Unresponsive, BCG-Relapsing and High Risk BCG-Naive Non-Muscle Invasive Urothelial Carcinoma of the BladderActive, not recruitingNCT03317158Phase 1/2
• Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi SarcomaCompletedNCT03316274Early Phase 1
• Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant LymphomaCompletedNCT03316144Phase 1
• Evolution of the Heart Function When Monitoring Immunotherapies Anti-cancerous Inhibiting PD-1Status unknownNCT03313544Phase 4

← Immune Checkpoint Inhibitors overview